U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07138001) titled 'Phase 2 Clinical Trial of KH617' on Aug. 15.
Brief Summary: To evaluate the efficacy and safety of KH617 for injection in combination with temozolomide versus investigator's choice therapy or KH617 monotherapy for recurrent glioblastoma
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Recurrent Glioblastoma
Intervention:
COMBINATION_PRODUCT: KH617+TMZ
use KH617 and TMZ(5/28) as Combination Product.
DRUG: KH617
Single Clinical trial investigational drug
DRUG: TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16
Comparator product, Two treatment options for physicians and subjects to choose from:
1. use ...